Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Research Applications

Executive Summary: Foretinib (GSK1363089) is a small-molecule ATP-competitive inhibitor that targets multiple receptor tyrosine kinases, including VEGFRs and Met, with low-nanomolar potency (APExBIO). It suppresses proliferation, migration, and invasion across diverse cancer cell lines at IC50 values as low as 0.4–9.6 nmol/L (DMSO, 37°C). Foretinib induces G2/M cell cycle arrest and blocks HGF-induced cell motility, consistent with its action on the HGF/Met pathway. In vivo, oral administration (30 mg/kg) reduces metastatic burden in ovarian cancer xenograft models. The product is manufactured and supplied for research use by APExBIO (A2974).

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFRs, Met, Ron, KIT, and Tie-2 are central regulators of tumor growth, angiogenesis, and metastasis. Aberrant activation of these RTKs correlates with increased proliferation, enhanced cell motility, and resistance to apoptosis in cancer cells (Schwartz 2022). Multikinase inhibitors like Foretinib (GSK1363089) are designed to disrupt these signaling pathways, offering a strategic approach for targeting heterogeneous tumor populations and overcoming compensatory survival mechanisms. Foretinib’s spectrum of activity makes it suitable for probing RTK-driven oncogenic processes and dissecting cross-talk among VEGF, HGF/Met, and related pathways in cancer models.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor that binds the intracellular kinase domains of several RTKs. Its primary targets include:

• VEGF Receptors: KDR (VEGFR2), Flt-1 (VEGFR1), Flt-4 (VEGFR3)
• HGF/Met: Hepatocyte growth factor receptor (HGFR/Met)
• Ron (MST1R), KIT (CD117), Flt-3, PDGFR α/β, Tie-2

IC50 values for kinase inhibition range from 0.4 to 9.6 nmol/L (in vitro kinase assays, 25°C, buffer pH 7.4). In cellular assays, Foretinib inhibits MET-mediated signaling in B16F10 melanoma, PC-3 prostate, A549 lung, and HT29 colon cancer cells with IC50 values of 21–23 nmol/L (Schwartz 2022).

Mechanistically, Foretinib blocks HGF-induced cell motility, impairs downstream signaling (including PI3K/AKT and MAPK/ERK cascades), and induces G2/M cell cycle arrest. These effects translate to reduced proliferation, migration, and invasion in functional assays.

Evidence & Benchmarks

• Foretinib inhibits Met, Ron, KDR, Flt-1, Flt-4, KIT, Flt-3, PDGFR α/β, and Tie-2 kinases with IC50 values between 0.4–9.6 nmol/L in biochemical assays (DMSO, 25°C, pH 7.4) (Schwartz 2022).
• Cellular MET inhibition (IC50 ≈ 21–23 nmol/L) is consistent in B16F10, PC-3, A549, and HT29 cell lines, using standard motility and proliferation assays (37°C, 5% CO₂) (Schwartz 2022).
• Foretinib induces G2/M cell cycle arrest, as shown by increased proportion of cells in G2/M phase after 24–48 hours of treatment (flow cytometry, PI staining) (Schwartz 2022).
• In vivo, oral dosing at 30 mg/kg reduces tumor burden and metastatic nodule formation in ovarian cancer xenograft models (athymic nude mice, daily x14 days) (Schwartz 2022).
• Foretinib is soluble at ≥31.65 mg/mL in DMSO but insoluble in water and ethanol (20–25°C, standard solubility assay) (APExBIO).

For a systems-level view of Foretinib's impact beyond basic kinase inhibition, see this article, which explores systems biology and novel mechanistic strategies not covered in this practical guide.

Applications, Limits & Misconceptions

Foretinib (GSK1363089) is intended for laboratory research use, enabling the study of multikinase inhibition in cancer cell lines and in vivo models. Experimental applications include:

• Cell viability and proliferation assays in metastatic and non-metastatic tumor lines
• Cell motility and invasion assays utilizing HGF-induced migration models
• In vivo xenograft and metastasis models, especially ovarian cancer
• Pathway dissection for VEGF, HGF/Met, and related RTK signaling

For an assay-focused protocol and troubleshooting guide, see this evidence-based article, which expands on integration in cell-based workflows, whereas the present content offers mechanistic context and product-specific benchmarks.

Common Pitfalls or Misconceptions

• Foretinib is not intended for clinical or diagnostic use. It is for research applications only (APExBIO).
• Solubility constraints: Foretinib is insoluble in water and ethanol; only DMSO or compatible organic solvents should be used for stock solutions (≥31.65 mg/mL).
• Storage stability: Solutions should be stored at -20°C and used promptly to avoid degradation; repeated freeze-thaw cycles may reduce potency.
• Not all cell lines are equally sensitive: Resistance mechanisms (e.g., downstream pathway mutations) may confound results; always use proper controls.
• Assay dependence: Cell death and proliferation outcomes may differ depending on the assay used (relative vs fractional viability) (Schwartz 2022).

This article clarifies the mechanistic and benchmark-driven use of Foretinib, whereas scenario-driven troubleshooting and comparative analyses are detailed in this scenario-focused article.

Workflow Integration & Parameters

To maximize reproducibility and interpretability, researchers should adhere to the following parameters when using Foretinib (GSK1363089):

• Solubility and Preparation: Dissolve Foretinib at ≥31.65 mg/mL in DMSO. Do not use water or ethanol as solvents.
• Storage: Store stock solutions at -20°C. Minimize freeze-thaw cycles.
• Assay Conditions: For cell-based assays, dilute DMSO stocks into culture media to achieve final concentrations (typically 1–100 nM). Maintain <0.1% DMSO v/v in culture to avoid solvent toxicity.
• In Vivo Dosing: Oral gavage at 30 mg/kg/day in mouse models is validated for anti-metastatic efficacy.
• Controls: Always include vehicle (DMSO) and pathway-specific positive/negative controls.

For advanced model-based experimentation and systems-level insights, reference this recent review, which extends the topic to systems biology and functional in vivo research.

Conclusion & Outlook

Foretinib (GSK1363089), available from APExBIO (A2974), provides a validated tool for dissecting RTK signaling, tumor cell behavior, and anti-metastatic mechanisms in cancer research. Its multikinase targeting, robust in vitro and in vivo activity, and well-characterized properties make it a preferred choice for mechanistic and translational studies. Continued adoption in complex models and systems biology is anticipated to further elucidate RTK-driven oncogenic networks and therapeutic resistance.